| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| William Winlow, Louise Profit, Paul Chris. Aripiprazole: the evidence of its therapeutic impact in schizophrenia. Core evidence. vol 1. issue 4. 2012-10-02. PMID:22496680. |
aripiprazole: the evidence of its therapeutic impact in schizophrenia. |
2012-10-02 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
aripiprazole: a review of its use in the management of schizophrenia in adults. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
oral aripiprazole (abilify®) is an atypical antipsychotic agent that is approved worldwide for use in adult patients with schizophrenia. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
in several well designed, randomized, clinical trials of 4-6 weeks duration, aripiprazole provided symptomatic control for patients with acute, relapsing schizophrenia or schizoaffective disorder. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
furthermore, following 26 weeks' treatment, the time to relapse was significantly longer for patients with chronic, stabilized schizophrenia receiving aripiprazole compared with those receiving placebo. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
several open-label, switching trials showed that aripiprazole provided continued control of symptoms in patients with schizophrenia or schizoaffective disorder. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
aripiprazole was generally well tolerated in patients with schizophrenia. |
2012-10-01 |
2023-08-12 |
Not clear |
| Jamie D Croxtal. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS drugs. vol 26. issue 2. 2012-10-01. PMID:22296317. |
in conclusion, oral aripiprazole provides an effective and well tolerated treatment alternative for the acute and long-term management of patients with schizophrenia. |
2012-10-01 |
2023-08-12 |
Not clear |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. |
2012-09-27 |
2023-08-12 |
human |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
the aim of the study was to investigate the effect of switching to aripiprazole on sexual dysfunction and the hypothalamic-pituitary-gonadal axis in male patients with schizophrenia. |
2012-09-27 |
2023-08-12 |
human |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
our results suggest that sexual dysfunction in schizophrenia patients seems to improve after switching to aripiprazole from other atypical antipsychotics (risperiodone, amisulpride, or olanzapine). |
2012-09-27 |
2023-08-12 |
human |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
aripiprazole is a dopamine d/d3 and serotonin 5-ht1a receptor partial agonist which is approved for treatment of schizophrenia. |
2012-09-13 |
2023-08-12 |
human |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
aripiprazole's intrinsic activities at d2 and d9 receptors were lower than those observed with partial agonists (terguride, bifeprunox, opc-4392 and (-)-3-ppp), which demonstrated clinically suboptimal improvement of positive symptoms of schizophrenia patients, and higher than that of sdz 208-912, which demonstrated incidence of extrapyramidal symptoms similar to haloperidol. |
2012-09-13 |
2023-08-12 |
human |
| Tetsuya Tanioka, Syoko Fuji, Mika Kataoka, Beth King, Masahito Tomotake, Yuko Yasuhara, Rozzano Locsin, Keiko Sekido, Kazushi Mifun. Retrospective study of Japanese patients with schizophrenia treated with aripiprazole. ISRN nursing. vol 2012. 2012-09-13. PMID:22970386. |
retrospective study of japanese patients with schizophrenia treated with aripiprazole. |
2012-09-13 |
2023-08-12 |
human |
| Tetsuya Tanioka, Syoko Fuji, Mika Kataoka, Beth King, Masahito Tomotake, Yuko Yasuhara, Rozzano Locsin, Keiko Sekido, Kazushi Mifun. Retrospective study of Japanese patients with schizophrenia treated with aripiprazole. ISRN nursing. vol 2012. 2012-09-13. PMID:22970386. |
the purpose of this retrospective study was to evaluate changes in clinical indicators which influence the quality of life (qol) of patients with schizophrenia treated by antipsychotic therapy before and after switching to aripiprazole. |
2012-09-13 |
2023-08-12 |
human |
| Tetsuya Tanioka, Syoko Fuji, Mika Kataoka, Beth King, Masahito Tomotake, Yuko Yasuhara, Rozzano Locsin, Keiko Sekido, Kazushi Mifun. Retrospective study of Japanese patients with schizophrenia treated with aripiprazole. ISRN nursing. vol 2012. 2012-09-13. PMID:22970386. |
a retrospective chart review of 27 patients diagnosed with schizophrenia and who were switched from one antipsychotic to aripiprazole was performed. |
2012-09-13 |
2023-08-12 |
human |
| Aleksandar Chanachev, Nicolas Ansermot, Séverine Crettol Wavre, Ute Nowotka, Maria-Eleni Stamatopoulou, Philippe Conus, Chin B Ea. Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment-resistant schizophrenia. Case reports in psychiatry. vol 2011. 2012-08-31. PMID:22937411. |
addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment-resistant schizophrenia. |
2012-08-31 |
2023-08-12 |
Not clear |
| Ravindra B Belgamwar, Hany George G El-Saye. Aripiprazole vs placebo for schizophrenia. Schizophrenia bulletin. vol 38. issue 3. 2012-08-30. PMID:22454550. |
aripiprazole vs placebo for schizophrenia. |
2012-08-30 |
2023-08-12 |
Not clear |
| John M Kane, Raymond Sanchez, Pamela P Perry, Na Jin, Brian R Johnson, Robert A Forbes, Robert D McQuade, William H Carson, W Wolfgang Fleischhacke. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. vol 73. issue 5. 2012-08-29. PMID:22697189. |
aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. |
2012-08-29 |
2023-08-12 |
Not clear |
| John M Kane, Raymond Sanchez, Pamela P Perry, Na Jin, Brian R Johnson, Robert A Forbes, Robert D McQuade, William H Carson, W Wolfgang Fleischhacke. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. vol 73. issue 5. 2012-08-29. PMID:22697189. |
to evaluate the efficacy and tolerability of a once-monthly intramuscular (im) depot formulation of the dopamine partial agonist aripiprazole as maintenance treatment in adults meeting dsm-iv-tr schizophrenia criteria. |
2012-08-29 |
2023-08-12 |
Not clear |